ANI PHARMACEUTICALS, INC
boothcheck covers ANI PHARMACEUTICALS, INC (ANIP) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• The mix is changing under the reported numbers: generics remain the largest revenue line at 43%, while Cortrophin Gel at 39% grew 42.1% in the first quarter of 2026 [Source: ANI Pharmaceuticals Q1 2026 results, May 8, 2026]. • Growth is being rented rather than owned, with the share count rising about 7.5% a year over the past four years and the FY2025 10-K describing a $325.0 million term loan drawn in September 2024 to finance the Alimera acquisition. • Payer policy is the swing variable, an
Is ANIP overvalued? See what's priced in →
268 institutional managers reported holding ANIP in 13F filings for the quarter ended 2026-03-31. 35 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 3.2M shares were sold short as of the 2026-06-15 count, about 15% of shares outstanding (10.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ANIP's share count grew 73.1% over the past five years even with $49.94M spent on repurchases. It pays a dividend, and has for 5 years running. Cash returned over the past three years: $3.59M in dividends and $43.82M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ANIP over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ANIP's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-09 | +13.5% | +15.5% |
| 2023-08-10 | +8.4% | -4.4% |
| 2023-11-09 | -17.9% | +6.8% |
| 2024-05-11 | +3.3% | -6.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ANIP's latest 8-K filings: 2026-08-24 (items 5.02, 9.01); 2026-08-07 (items 2.02, 7.01, 9.01); 2026-05-21 (items 5.02, 5.07, 9.01); 2026-05-13 (items 7.01, 9.01); 2026-05-08 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.